Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroblastoma 1

Interventions

Cyclophosphamide 14Temozolomide 10Magnetic Resonance Spectroscopy 10Biopsy 9dinutuximab 8X-Rays 8Specimen Handling 8Irinotecan 8Phantoms, Imaging 7fludarabine 6Topotecan 6Nuclear Medicine Department, Hospital 6Vincristine 53-Iodobenzylguanidine 5fludarabine phosphate 4Melphalan 4Granulocyte-Macrophage Colony-Stimulating Factor 4Etoposide 4tipifarnib 3sargramostim 3Radiotherapy 3Isotretinoin 3Filgrastim 3Doxorubicin 3Carboplatin 3ulixertinib 2tazemetostat 2selpercatinib 2saponin QA-21V1 2pembrolizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroblastoma × IL32 protein, human × 90 days × Clear all
NCT02573896 2026-03-23

Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells

New Approaches to Neuroblastoma Therapy Consortium

Phase 1 Active not recruiting
13 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡